GNI Group Ltd.
Stock Price Chart
2026/05/15 UpdatedPrice Trend
2026/05/15 UpdatedPrice & Trading Details
2026/05/15 UpdatedPRICE
TRADING
Analyst Recommendations 3 analysts
Updated 2026/05/01Earnings Calendar
Updated 2026/05/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/02/12 | ¥224.64 | ¥-74.44 | -133.1% |
| 2025/11/13 | ¥10.82 | ¥8.54 | -21.1% |
| 2025/08/14 | ¥-109.70 | ¥-7.62 | +93.1% |
| 2025/05/15 | ¥27.86 | ¥-10.57 | -137.9% |
Shareholder Composition
Updated 2026/05/01Financial Performance
2026/05/10 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥12,690M | ¥17,419M | ¥26,011M | ¥23,612M |
| Gross Profit | ¥11,090M | ¥14,745M | ¥22,431M | ¥18,037M |
| Operating Income | ¥1,625M | ¥1,378M | ¥13,109M | ¥1,402M |
| Pretax Income | ¥1,755M | ¥1,638M | ¥13,863M | ¥2,119M |
| Net Income | ¥1,066M | ¥389M | ¥8,094M | ¥1,098M |
| EPS | ¥22.08 | ¥8.11 | ¥165.56 | ¥21.15 |
| Operating Margin | 12.80% | 7.91% | 50.40% | 5.94% |
| Balance Sheet | ||||
| Total Assets | ¥30,296M | ¥33,907M | ¥64,269M | ¥71,943M |
| Total Equity | ¥18,860M | ¥20,970M | ¥33,794M | ¥36,446M |
| Total Liabilities | ¥11,436M | ¥12,937M | ¥30,475M | ¥35,497M |
| Cash | ¥14,352M | ¥11,049M | ¥21,633M | ¥10,115M |
| Interest-bearing Debt | ¥1,126M | ¥537M | ¥3,699M | ¥7,206M |
| Equity Ratio | 62.25% | 61.84% | 52.58% | 50.66% |
| D/E Ratio | 0.06 | 0.03 | 0.11 | 0.20 |
| Cash Flow | ||||
| Operating CF | ¥552M | ¥393M | ¥6,549M | -¥3,164M |
| Investing CF | -¥261M | -¥4,116M | -¥6,843M | -¥10,361M |
| Financing CF | ¥2,853M | -¥646M | ¥10,687M | ¥694M |
| Free CF | -¥142M | -¥1,547M | ¥4,473M | -¥4,701M |
| Efficiency | ||||
| ROE | 5.65% | 1.85% | 23.95% | 3.01% |
| ROA | 3.52% | 1.15% | 12.59% | 1.53% |
Latest IR Information
-
[GNI Group] New Drug Approval Application Accepted in China | May 2026
GNI Group's consolidated subsidiary Gyre Pharmaceuticals has received formal acceptance of its new drug application for F351, a treatment for liver fibrosis caused by chronic hepatitis B, in China, with priority review also designated, boosting expectations for future approval and...
Read more -
[GNI Group] Q1 FY2026 Earnings｜Sales $22.5 million (YoY +1.8%)
GNI Group’s subsidiary Gyre Therapeutics recorded sales of $22.5 million, operating loss of ¥1,495 million, and net loss of ¥1,574 million in Q1 FY2026. Despite increased R&D and sales promotion expenses leading to wider losses, full-year forecasts remain unchanged.
Read more -
[GNI Group] Strengthening of the Representative Executive Officer System and Executive Appointments for Subsidiaries | May 2026
GNI Group is implementing changes in the representative executive officer and executive appointments for its subsidiaries to strengthen its global strategy and management foundation. Ying Luo has been appointed as the new CEO, and Ryosuke Matsui has been added as...
Read more -
[GNI Group] Completion of U.S.-China Subsidiary Acquisition｜May 2026
GNI Group has completed the full acquisition of Gyre Therapeutics' subsidiaries in the U.S. and China, promoting global expansion and product portfolio growth.
Read more -
Announcement of Completion of Enrollment of First Subject in Phase 2/3 Clinical Trial of Pirfenidone for Expanded Indication in Cancer-Related Pulmonary Complications
In April 2026, completed enrollment of the first subject in the Phase 2/3 clinical trial for the expanded indication of pirfenidone targeting radiation-induced lung injury (RILI).
Read more
Latest News (5 items)
-
Average Analyst Rating: strong_buy
Average Target Price: ¥4,400
Rating Score: 1.00 (Based on 3 analysts)
※1=Strong Buy, 5=Strong Sell
GNI Group Widens Q1 Loss as Drug Investment and Reorganization Weigh on Earnings - TipRanks ↗
Company Information
About
GNI Group Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of pharmaceuticals and biomaterials in Japan, China, and the United States. It operates in two segments, Pharmaceutical Business and Medical Equipment Business. The company offers ETUARY for the treatment of idiopathic pulmonary fibrosis; H-GENIN Crush-Mix for the treatment of bone defects; AltiPly for the treatment of acute and chronic wounds; and orthobiologics products. It also develops ETUARY which is in Phase III clinical trial for the treatment of pneumoconiosis, dermatomyositis interstitial lung disease, and systemic sclerosis-associated interstitial lung disease; and F351 which is in Phase III clinical trial for the treatment of chronic hepatitis B liver fibrosis. In addition, the company is involved in the development of ETUARY which is in Phase II clinical trial for the treatment of radiation-induced lung injury with or without immune-related pneumonitis; F573 which is in Phase II clinical trial for the treatment of acute liver failure and acute-on-chronic liver failure; F351 which is in Phase I clinical trial for the treatment of MASH-advanced liver fibrosis; and F230 which is in Phase I clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops CG001419 which is in Phase Ia clinical trial for the treatment of acute and chronic pain; CG001419 which is in Phase Ia clinical trial for the treatment of solid tumors; and CG009301 which is in Phase Ia clinical trial for the treatment of leukemia and MYC+ cancers. The company was incorporated in 2001 and is headquartered in Chuo, Japan.
